Nasdaq · Medicinal Chemicals & Botanical Products
9 entities across 3 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-26 — see the exhibit.
| Entity | Jurisdiction | Note |
|---|---|---|
| Cronos Growing Company Inc. | Canada | |
| Hortican Inc. | Canada | |
| Peace Naturals Project Inc. | Canada | |
| Cronos Research Labs Ltd. | Israel | |
| Cronos Israel G.S. Store Ltd. | Israel | |
| Cronos Israel G.S. Cultivation Ltd. | Israel | |
| Cronos Israel G.S. Pharmacy Ltd. | Israel | |
| Cronos Israel G.S. Manufacturing Ltd. | Israel | |
| CGM B.V. | Netherlands |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $46.7M | −$73.1M | −$173.9M | -55.3% | 351,576,848 |
| FY2021 | $74.4M | −$396.1M | −$164.8M | -23.6% | 370,390,965 |
| FY2022 | $91.9M | −$168.7M | −$92.4M | 13.0% | 376,961,797 |
| FY2023 | $87.2M | −$74.0M | −$45.3M | 13.7% | 380,964,739 |
| FY2024 | $117.6M | $41.1M | $6.4M | 21.4% | 385,557,002 |
| FY2025 | $146.6M | −$9.4M | $149,000 | 42.8% | 383,468,522 |
6 institutions tracked — 4 added, 0 reduced.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | Hedge fund | 1,278,285 | +422,628 | $3.6M |
| MORGAN STANLEY | Active fund | 304,527 | +54,132 | $846,586 |
| BANK OF AMERICA CORP /DE/ | Active fund | 157,631 | +41,814 | $438,214 |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 577,274 | +25,638 | $1.6M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register. These filings span 2025-Q4–2026-Q2 rather than a single quarter, because filers report on their own schedules.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Cronos Group Inc. files under SIC 2833 — all 8 medicinal chemicals & botanical products companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
